$46.73
0.00%
Nasdaq, Aug 30, 12:14 am CET
ISIN
US00973Y1082
Symbol
AKRO

Akero Therapeutics Inc Stock price

$46.73
-0.76 1.60% 1M
-2.39 4.87% 6M
+18.91 67.97% YTD
+19.84 73.78% 1Y
+34.44 280.23% 3Y
+14.13 43.34% 5Y
+30.73 192.06% 10Y
+30.73 192.06% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.21 0.45%
ISIN
US00973Y1082
Symbol
AKRO
Industry

Key metrics

Basic
Market capitalization
$3.7b
Enterprise Value
$3.0b
Net debt
positive
Cash
$742.3m
Shares outstanding
79.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.6
Financial Health
Equity Ratio
90.8%
Return on Equity
-33.6%
ROCE
-30.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-321.5m | $-351.7m
EBIT
$-321.5m | $-352.7m
Net Income
$-284.0m | $-304.4m
Free Cash Flow
$-253.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-37.1% | -23.2%
EBIT
-37.1% | -23.6%
Net Income
-39.3% | -20.8%
Free Cash Flow
-31.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.5
FCF per Share
$-3.2
Short interest
11.9%
Employees
63
Rev per Employee
$0.0
Show more

Is Akero Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Akero Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Akero Therapeutics Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Akero Therapeutics Inc forecast:

Buy
94%
Hold
6%

Financial data from Akero Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
15% 15%
-
- Research and Development Expense 280 280
42% 42%
-
-321 -321
37% 37%
-
- Depreciation and Amortization 0.02 0.02
100% 100%
-
EBIT (Operating Income) EBIT -321 -321
37% 37%
-
Net Profit -284 -284
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Akero Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akero Therapeutics Inc Stock News

Neutral
GlobeNewsWire
5 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025, at 10:45 a....
Neutral
GlobeNewsWire
18 days ago
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH
Neutral
The Motley Fool
25 days ago
Akero (AKRO) Q2 Loss Narrows 6%
More Akero Therapeutics Inc News

Company Profile

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Head office United States
CEO Andrew Cheng
Employees 63
Founded 2017
Website akerotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today